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8th Annual Angioma Alliance 
CCM SCIENTIFIC MEETING 
November 15-16, 2012 
DoubleTree Bethesda – Washington, DC 
Ballroom D 
 
DAY 1 | THURSDAY, NOVEMBER 15TH 
 
7:45  WELCOME & OPENING REMARKS 
  Amy Akers & Sara Sukalich – Angioma Alliance 
 
SESSION I – PROTEOMICS, STRUCTURE & FUNCTION 
  DOUG MARCHUK, SESSION CHAIR 
   
8:00  New insights into the structure and function of CCM proteins 
Titus Boggon – Yale University School of Medicine 
 
8:20  Proteomics characterization of CCM complexes 
Anne-Claude Gingras – Samuel Lunenfeld Research Institute 
   
8:40 Structural Basis of the Junctional Anchorage of the Cerebral 
Cavernous Malformations Complex 
Alexandre Gingras – University of California San Diego 
 
SESSION II – SIGNALING 
BRENT DERRY, SESSION CHAIR 
 
9:00 Defining the Ccm3 signaling pathway in a zebrafish model of CCM 
disease 
Bilge Yoruk** – Sick Kids Research Institute  
 
9:20  CCM3 and senescence 
Juan Zalvide – University of Santiago de Compostela 
  
9:40  COFFEE BREAK 
 
10:00  CCM3 functions in brain development 
Angeliki Louvi – Yale School of Medicine 
 
10:20 CCM3 regulates endosome recycling in the C. elegans excretory cell 
Ben Lant – Sick Kids Research Institute 
 
10:40  Novel Endothelial Signaling in CCM 
Rebecca Stockton – University of California Los Angeles 
 
11:00 Further Studies of Fasudil Treatment in Murine Models of Cerebral 
Cavernous Malformation Disease  
Robert Shenkar – University of Chicago 
 
11:20  DISCUSSION OF SESSIONS I & II 
 
12:00  Lunch | Oz Restaurant 
 
SESSION III – VASCULAR BIOLOGY & INFLAMMATION 
  BRANT WEINSTEIN, SESSION CHAIR 
 
1:00 The CCM2 paralogue CCM2L opposes canonical cerebral cavernous 
malformation signaling in endothelial cells during cardiovascular 
growth 
Xiangjian Zheng – University of Pennsylvania  
 
1:20 Loss of Notch signaling in the adult endothelium: implications for 
CCM 
Andreas Fischer – German Cancer Research Center Heidelberg (DKFZ) 
 
1:40 The recombinant antibody construction and restricted B cell 
repertoire in Human Cerebral Cavernous Malformation (CCM) 
Changbin Shi – University of Chicago 
 
2:00 Decreased KRIT1 expression leads to increased vascular 
permeability and modifies inflammatory responses in vivo. 
Angela Glading – University of Rochester 
 
2:20 CCM2 intersects a novel pathway of cytokine mediated vascular 
instability 
Dean Li – University of Utah 
 
2:40  COFFEE BREAK 
 
SESSION IV – LESION GENESIS 
  KEVIN WHITEHEAD, SESSION CHAIR 
 
3:00 Novel insights into the relationship between KRIT1 and ROS 
homeostasis: KRIT1 loss-of-function causes a ROS-dependent 
upregulation of transcription factors involved in oxidative stress 
response 
Saverio Francesco Retta – University of Torino 
 
3:20 Exploring the Implications of a Two-Hit Mechanism in Cerebral 
Cavernous Malformations  
David McDonald** - Duke University Medical Center 
 
3:40 CCM3-dependent EC-SMC/pericyte interactions in CCM lesion 
development mouse models and mechanistic studies 
Wang Min – Yale University 
 
4:00 Angiogenesis is Required for Cavernous Malformation Development 
Kevin Whitehead – University of Utah 
 
4:20   DISCUSSION OF SESSIONS III & IV 
5:00  END OF DAY 1 
7:00  DINNER | BALLROOM C 
 
 
DAY 2 | Friday, November 16th  
 
8:30 WELCOME 
Connie Lee – Angioma Alliance & CCM3 Action 
 
SESSION V – MAGNETIC RESONANCE IMAGING TECHNOLOGIES 
LESLIE MORRISON, SESSION CHAIR 
 
8:40  Quantitative Iron Burden as a Biomarker of Cumulative 
Hemorrhages in Cerebral Cavernous Malformations: Studies in 
Mouse and Man 
Luying (Ryan) Li** – West China Medical School of Sichuan University & 
University of Chicago  
 
9:00 Novel Magnetic Resonance Imaging Biomarkers of Human CCM 
Disease: Dynamic Contrast-Enhanced Quantitative Perfusion  
Abdul Ghani Mikati** – University of Chicago 
 
9:20  White Matter Hyperintensities in CHM CCM1 
Blaine Hart – University of New Mexico 
 
9:40  COFFEE BREAK 
 
SESSION VI – CLINICAL STUDIES  
ISSAM AWAD, SESSION CHAIR 
 
10:00 Spectrum of Human Causative Mutations in the KRIT1, CCM2 and 
PDCD10 Genes 
James Weber – PreventionGenetics 
 
10:20 Clinical Factors Associated with Lesion Count in Familial Cerebral 
Cavernous Malformation Type 1 Patients with the Common Hispanic 
Mutation 
Hélène Choquet** – University of California San Francisco 
 
10:40  Cutaneous Features of the CCM1-CHM Cohort  
Leslie Morrison – University of New Mexico 
 
11:00 Outcome after surgical or conservative management of cerebral 
cavernous malformations: a prospective, population-based cohort 
study	  	  
Margaret A. Horne** - University of Edinburgh 
 
11:20  DISCUSSION OF SESSION V & VI 
12:00  LUNCH | OZ RESTAURANT 
 
Session VII – Panel Discussion of Clinical Trails for CCM 
 
1:00  Biomarkers 
  Issam Awad – University of Chicago 
1:10  Recruitment Strategies 
  Leslie Morrison – University of New Mexico 
1:20  Trials & Research Consortia 
  William Young – University of California San Francisco 
1:30  Food & Drug Administration Perspective 
Gumei Liu – Rare Diseases Program Office of New Drugs 
1:40  National Institutes of Health Perspective 
  Claudia Moy – NINDS office of Clinical Research 
 
1:50  OPEN DISCUSSION 
 
3:00  CLOSE OF MEETING 
 
 
MEETING SPONSORS 
ANGIOMA ALLIANCE 
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE 
CCM3 ACTION 
INNOLYST (PATIENT CROSSROADS) 
 
**Trainee Travel Award Winner 
